poisar

Stock

PTC Therapeutics, Inc. PTCT

$71.70-0.38%

Overview

PTCT market data

Price History

PTCT price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
8.80
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$7.73
Diluted earnings per share over the trailing twelve months.
Beta
0.49
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-3.8%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$45.43 – $90.87
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $6B · P/B 14.29 · P/S 5.95.

Company News

10 captured
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122Benzinga · Aug 14, 2026, 2:23 PM
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'Benzinga · Aug 13, 2026, 4:28 PM
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109Benzinga · Aug 13, 2026, 1:36 PM
8-K filing — PTC THERAPEUTICS, INC. (PTCT)SEC EDGAR · Aug 13, 2026, 11:00 AM
PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory ApprovalsBenzinga · Aug 12, 2026, 8:14 PM
Top 3 Health Care Stocks You'll Regret Missing This QuarterBenzinga · Aug 4, 2026, 10:04 AM
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104Benzinga · Jul 31, 2026, 5:14 PM
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106Benzinga · Jul 31, 2026, 2:38 PM
PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B EstBenzinga · Jul 30, 2026, 8:04 PM
PTC Therapeutics Q2 EPS $0.92 Beats $0.23 Estimate, Sales $360.519M Beat $298.963M EstimateBenzinga · Jul 30, 2026, 8:01 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock